📊 Pharmaceutical market access & pricing intelligence

Stop monitoring the market manually — let GPI Pulse™ do it for you

GPI Pulse™ is our subscription-based competitive monitoring and market access platform — bringing pricing, reimbursement, HTA intelligence, and policy tracking across 60+ markets together in one place. With dedicated capabilities for MFN, Globe, and Guard policy analysis, it gives your team the data depth to turn risk into predictable outcomes.

200M+ Data points across pricing, reimbursement & HTA
60+ Markets in pricing & reimbursement data
100+ Markets in IRP reference pricing matrix
<24hrs Typical support response time
⚡ MFN · Globe · Guard

Navigating US drug pricing policy changes? GPI Pulse™ provides the IRP intelligence, global launch sequence data, and pricing analogue depth your team needs to control MFN exposure from Day One — not after flexibility is lost.

Talk to our team →

Trusted by leading pharmaceutical companies

Big Pharma Emerging Biotech Mid-size Specialty CROs & Consultancies

See GPI Pulse™ in action

Watch our team walk through how GPI Pulse™ works — from the data universe through to pricing, HTA, and reference pricing intelligence. Use the chapter buttons below to jump to the section most relevant to you.

Skip to:
Interested in what you've seen?

Talk to our team about a GPI Pulse™ subscription — we'll show you exactly what's available for your therapy area, markets, and MFN use case.

Book a demo →

Market intelligence shouldn't require a team of analysts

Staying on top of competitive activity, pricing changes, HTA decisions, and evolving policy landscapes means manually retrieving information from multiple sources, across different countries, in different languages — then repeating that entire process as markets evolve. It is slow, inconsistent, and impossible to scale.

Fragmented sources across 60+ marketsRelevant data sits across dozens of country-level databases, regulatory bodies, and payer publications — each in a different format, often in a different language.

Constant manual rework as markets evolvePricing decisions, HTA outcomes, and reimbursement status change regularly — meaning any analysis becomes outdated almost immediately without a dedicated process to maintain it.

MFN, Globe & Guard risk caught too lateMFN exposure is created by the launch and pricing decisions you make every day. Without continuous IRP intelligence and launch sequence visibility, teams only see the problem once flexibility is already gone.

Time lost to research instead of strategyWhen teams spend their time pulling data together, they have less capacity for the analysis and decision-making that actually drives competitive advantage.

GPI Pulse™ removes the burden of manual market intelligence. Everything is structured, standardised, and continuously updated — so our clients spend less time retrieving information and more time acting on it.

— GPI Pulse™ product team

What GPI Pulse™ brings to your team

A single subscription platform combining 200M+ data points across pricing, reimbursement, and HTA — structured, standardised, continuously updated, and configurable to your organisation's data workflows.

Price & reimbursement data

Availability, reimbursement status, and country-specific net pricing across 60+ markets — all in one consistent, source-transparent view. Historical pricing tracks how prices have evolved over time, including relevant analogues, with multi-currency conversion built in. Critical for understanding where MFN-relevant price points are forming across global markets.

60+ pricing markets

Cost of treatment analysis

Go beyond pack-level pricing with cost-of-treatment data calculated per day, per month, and per annum by country and indication. Gives a representative, comparable view of drug cost across different markets and dosing schedules — without manual calculation — supporting robust policy and access modelling.

60+ pricing markets

HTA outcomes & assessment data

Structured HTA data including assessment publications, clinical trial comparators, pricing analogues, payer decisions, and reimbursement timelines — all linked to original source documents. Understand exactly what shaped payer perception in any given market, and track how reimbursement timelines benchmark against your own launch planning.

30+ HTA markets

IRP matrix & MFN/Globe/Guard intelligence

A comprehensive IRP matrix across 100+ markets detailing referencing rules, matched reference countries, referenced price levels, and policy-specific considerations. Understand how early launch prices enter IRP baskets, predict when they will be picked up by referencing markets, and model alternative launch sequences to reduce MFN, Globe, and Guard exposure before it becomes locked in.

100+ IRP markets

Custom alerts & policy monitoring

Set up proactive alerts by country, therapy class, indication, or event type — including policy-driven changes such as MFN-related pricing announcements or IRP rule updates — so you are always informed the moment something changes in your space. No relevant development will slip through the net.

60+ markets

Launch trends, templates & configurable data feeds

Visualise historical launch sequencing and country order trends to inform your own launch strategy. Purpose-built custom reporting templates generate tailored outputs with a click. For teams requiring end-to-end integration, GPI Pulse™ supports configurable data feeds — connecting market intelligence directly into your internal workflows and systems without manual export steps.

60+ markets

Built for every team that needs market intelligence

Used across top 10 global pharmaceutical companies and small to mid-sized biotech — by different functions, at every stage of the drug development pipeline.

Market Access Teams

Stay ahead of competitive activity, track availability and reimbursement status across key markets, and build a clear picture of the landscape before and after launch — without manually chasing data across multiple sources.

  • Real-time availability and reimbursement status by market
  • Competitive landscape tracking across therapy area
  • HTA decision monitoring with source documentation
  • Time-to-reimbursement benchmarks for launch planning

Pricing & Market Access Directors

Access country-level net pricing, multi-currency comparisons, a full IRP matrix, and pricing analogue data across 60+ markets. Model the reference pricing implications of your launch sequencing decisions and control MFN, Globe, and Guard exposure from Day One — not once it is already embedded.

  • Country-level net pricing with historical tracking
  • IRP matrix covering referencing rules across 100+ markets
  • MFN/Globe/Guard exposure modelling via launch sequence data
  • Pricing analogue benchmarking for portfolio governance

Clinical & Feasibility Teams

Use HTA outcomes, reimbursement timelines, and patient copayment data to support trial planning and feasibility assessments — understanding the payer landscape and policy environment before your study design is finalised.

  • HTA assessment data with comparator and endpoint detail
  • Reimbursement timelines by country for trial planning
  • Patient copayment data for access modelling
  • Historical event tracking to understand payer trajectory

Global coverage, local precision

Pricing and reimbursement data across 60+ markets, HTA outcomes across 30+ markets, and IRP reference pricing intelligence across 100+ markets — standardised, translated, and continuously updated across the world's most complex pricing environments.

🇩🇪 Germany 🇫🇷 France 🇬🇧 United Kingdom 🇮🇹 Italy 🇪🇸 Spain 🇺🇸 United States 🇯🇵 Japan 🌏 APAC 🌍 GCC 🌐 Nordics 🌎 LatAm ⚡ MFN · Globe · Guard
60+

Markets with pricing & reimbursement data

30+

Markets with HTA assessment data

100+

Markets in IRP reference pricing matrix

<24hrs

Typical support response time

What teams typically ask us

Answers to the questions that come up most in our conversations with market access, pricing, and clinical teams.

How does GPI Pulse™ help us manage MFN, Globe, and Guard risk?

+
MFN exposure is not accidental — it is created by the launch and pricing decisions teams make during development and commercialisation. GPI Pulse™ provides the data foundation to manage that risk proactively. The IRP matrix across 100+ markets lets you identify which markets will reference your early launch price and when, while global launch sequence data enables you to model alternative sequencing strategies before flexibility is lost. Pricing analogue data from comparable assets adds further context, and proactive policy alerts ensure your team stays informed as MFN, Globe, and Guard regulations develop. The goal is to move from reacting to MFN pressure to building MFN considerations into planning from Day One.

How is GPI Pulse™ different from going directly to individual data sources?

+
GPI Pulse™ aggregates and standardises data from multiple underlying sources into one consistent, analysis-ready format — saving you the time and cost of managing separate subscriptions and manual retrieval. We also translate key source documents, removing language barriers across non-English markets. Clients consistently highlight the depth of standardisation, the data transparency, and the significant time saving compared to maintaining their own workflows. For teams needing tighter system integration, configurable data feeds connect GPI Pulse™ directly into your internal processes.

How often is the data in GPI Pulse™ updated?

+
GPI Pulse™ is continuously updated as new pricing decisions, reimbursement changes, HTA outcomes, and policy developments are published. You always have access to the latest market intelligence without having to rerun the same research. For time-sensitive updates — including policy announcements relevant to MFN, Globe, or Guard — custom alerts let you set up proactive notifications so you are informed the moment something changes in your area of interest.

What does the IRP matrix cover, and why does it matter for launch sequencing?

+
The IRP matrix covers over 100 markets and details the referencing rules in each — which countries reference which markets, the price level referenced, and any policy-specific conditions that apply. This is particularly valuable for launch sequencing strategy: a pricing decision in one market can cascade across multiple IRP baskets within 12–24 months, creating MFN-style expectations in higher-value markets. Understanding this dynamic during planning — rather than after launch — is where GPI Pulse™ provides its greatest advantage.

Can GPI Pulse™ support both early pipeline work and post-launch monitoring?

+
Yes — GPI Pulse™ is used at all stages of the drug development pipeline. Early-stage teams use it for competitive landscape assessment, pricing analogue identification, and feasibility planning. Launch teams use it to track time-to-reimbursement, inform sequencing strategy, and model MFN risk before decisions are locked in. Post-launch, it supports ongoing competitive monitoring, price change tracking, and policy surveillance. Different functions within the same organisation often use it for different purposes simultaneously.

Ready to see GPI Pulse™ for your therapy area?

Talk to a GPI specialist about what GPI Pulse™ can deliver for your team — including how we support MFN, Globe, and Guard risk management across your portfolio.

Your data stays confidential Continuously updated data 60+ pricing markets, 100+ IRP markets

GPI Pulse™ — market access intelligence & MFN risk management for global pharma teams.

Skip to content